Ignite Creation Date:
2025-12-25 @ 2:51 AM
Ignite Modification Date:
2025-12-26 @ 1:32 AM
Study NCT ID:
NCT00061633
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2003-05-30
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Sponsor:
Cumberland Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-06
Start Date Type:
None
Primary Completion Date:
2004-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2004-01
Completion Date Type:
ACTUAL
First Submit Date:
2003-05-30
First Submit QC Date:
None
Study First Post Date:
2003-06-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2009-12-02
Results First Submit QC Date:
None
Results First Post Date:
2010-01-11
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-01-14
Last Update Post Date:
2019-01-16
Last Update Post Date Type:
ACTUAL